<div id="readability-page-1"><div><p>(MT Newswires) -- HOB Biotech's (SHA:688656) Shanghai subsidiary and Immunotek completed enrollment and dosing for the phase 3 clinical trial of its MM09 sublingual desensitization spray, according to a Thursday filing with the Shanghai Stock Exchange.</p><p> The multicenter phase 3 clinical trial targets allergies from house dust mites and dust mites, the filing said.</p><p> The company has also obtained import permits for the drug for indications for cat and dog hair and house dust mite allergens in both Hong Kong and Macao, the filing said.</p><p>Shares rose 1% during late afternoon trading on Wednesday.</p></div></div>

浩欧博

<p>浩欧博在上海的子公司已为其针对尘螨过敏的 MM09 舌下脱敏喷雾剂的第三阶段临床试验招募了首位患者。该公司还获得了在香港和澳门针对猫狗毛过敏原的药物进口许可证。此消息发布后，周三下午的交易中，股价上涨了 1%</p>

浩欧博上海子公司为抗过敏产品的临床试验招募了首位患者